Kelesidis Theodoros, Moser Carlee, Stein James H, Brown Todd T, Tran Thuy Tien T, Ribaudo Heather J, Dube Michael P, Yang Otto O, Currier Judith S, McComsey Grace A
David Geffen School of Medicine at UCLA.
Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. Epub 2016 Jun 28.
It is unclear whether differential roles of CD4(+) versus CD8(+) T-cell senescence/exhaustion and effects of antiretroviral therapy (ART) on these processes may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection. In a prospective 96-week trial, 328 HIV-infected ART-naive participants were randomly assigned to receive tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir. Markers of CD4(+) T-cell senescence (ie, the percentage of CD28(-)CD57(+) cells among CD4(+) T cells ) and CD4(+)/CD8(+) T-cell exhaustion (ie, the percentage of PD-1(+) cells among CD4(+)/CD8(+) T cells) decreased after ART. There were no changes in markers of CD8(+) T-cell senescence after ART and no differential changes in all markers in ART groups. Senescent CD4(+) and CD8(+) T cells may have differential roles in HIV pathogenesis.
目前尚不清楚CD4(+)与CD8(+) T细胞衰老/耗竭的不同作用以及抗逆转录病毒疗法（ART）对这些过程的影响是否会导致接受治疗的1型人类免疫缺陷病毒（HIV）感染者发病。在一项为期96周的前瞻性试验中，328名未接受过ART治疗的HIV感染者被随机分配接受替诺福韦-恩曲他滨联合阿扎那韦/利托那韦、达芦那韦/利托那韦或拉替拉韦治疗。ART治疗后，CD4(+) T细胞衰老标志物（即CD4(+) T细胞中CD28(-)CD57(+)细胞的百分比）和CD4(+)/CD8(+) T细胞耗竭标志物（即CD4(+)/CD8(+) T细胞中PD-1(+)细胞的百分比）降低。ART治疗后CD8(+) T细胞衰老标志物没有变化，且ART治疗组所有标志物均无差异变化。衰老的CD4(+)和CD8(+) T细胞在HIV发病机制中可能具有不同作用。
